Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?

24.12.24 13:17 Uhr

Werte in diesem Artikel
Aktien

69,00 EUR 1,00 EUR 1,47%

Indizes

6.040,0 PKT 66,0 PKT 1,10%

Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests aimed at detecting H5N1 bird flu. The ASRs are being developed on the company’s Panther Fusion system, a fully automated molecular testing platform that allows labs to quickly consolidate and run multiple assays for women's health, infectious disease and SARS-CoV-2 (COVID-19) testing.The latest development builds on the company’s existing strong portfolio of diagnostic solutions, including assays used for the detection of COVID-19.Predicting HOLX Stock Movement Following the NewsSince the announcement on Dec. 18, HOLX shares edged up 0.3%, finishing at $72.50 yesterday. Hologic’s Panther Fusion SARS-CoV-2 assay and the Aptima SARS-CoV-2 assay have played a critical role in the global pandemic response, with the company continuing to innovate in this area. In 2023, it received the FDA’s clearance for a test that can detect SARS-CoV-2, influenza A and B and RSV in a single patient sample. We expect the latest development to positively boost market sentiment toward HOLX stock.Hologic currently has a market capitalization of $16.26 billion. The company’s earnings yield of 5.99% compares favorably to the industry’s yield of - 4.65%. It delivered an earnings beat of 3.1%, on average, in the trailing four quarters.Importance Behind Hologic’s Latest CollaborationH5N1 bird flu, also known as avian influenza A (H5N1), is spreading among wild birds globally and causing outbreaks in poultry and dairy cows in the United States, with several recent cases reported among workers exposed to these infected animals. Illness from the virus in the United States has been mild but severe in other countries. To prepare for if the current outbreak worsens, Hologic is partnering with the CDC to develop reagents that may be used for H5N1 testing.The contract will fund proof-of-concept development of ASRs — primers and probes in this case — that could eventually be incorporated into laboratory-developed tests (LDTs) designed to detect H5N1. While Hologic does not currently intend to make these ASRs commercially available, the company may explore future commercialization should the need for rapid implementation of H5N1 testing arise.Image Source: Zacks Investment ResearchAmong 1,700 Panther systems installed in the U.S. public health laboratories, hospitals and private reference laboratories, nearly 500 of them are Panther Fusion systems. These can generate more than 1,000 results in 24 hours and have the flexibility to rapidly scale up testing capacity without the need for additional instruments or operator training in the event of an outbreak or pandemic. The Open Access functionality on the system enables labs to develop and automate their LDTs with the FDA-approved in vitro diagnostic (IVD) assay workflows, reducing time and labor.More Updates From HologicAt the RSNA (Radiological Society of North America) 2024 Annual Meeting this month, Hologic presented new research demonstrating the favorable performance of its Genius AI Detection 2.0 software across diverse patient populations. The company also announced plans to introduce its next-generation Genius AI Detection PRO solution in the United States.Industry Prospects Favoring HologicPer a research report, the global poultry diagnostics market was valued at $772.4 million in 2023 and is projected to grow at a compound annual rate of 9.8% through 2030. One of the key factors driving the market’s growth is the increasing prevalence of poultry diseases, which has heightened the need for effective diagnostic solutions. Also, technological advancements in diagnostic tools have improved the accuracy and efficiency of disease detection.HOLX Stock Price PerformanceIn the past year, Hologic shares have risen 2% compared with the industry’s 4.2% growth.HOLX’s Zacks Rank & Key PicksHologic currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space are Penumbra PEN, Haemonetics HAE and Phibro Animal Health PAHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Penumbra shares have dropped 7% in the past year. Estimates for the company’s 2024 earnings per share have increased 2 cents to $2.81 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.Estimates for Haemonetics’ fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have dropped 12.3% in the past year against the industry’s growth of 11.2%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 1.9% to $1.62 in the past 30 days. Shares of the company have surged 93% in the past year compared with the industry’s 11.1% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Bird

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Bird

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Hologic IncShs

Analysen zu Hologic IncShs

DatumRatingAnalyst
01.08.2019Hologic BuyNeedham & Company, LLC
02.05.2019Hologic BuyNeedham & Company, LLC
31.01.2019Hologic BuyNeedham & Company, LLC
09.10.2018Hologic NeutralUBS AG
01.08.2018Hologic BuyNeedham & Company, LLC
DatumRatingAnalyst
01.08.2019Hologic BuyNeedham & Company, LLC
02.05.2019Hologic BuyNeedham & Company, LLC
31.01.2019Hologic BuyNeedham & Company, LLC
01.08.2018Hologic BuyNeedham & Company, LLC
03.05.2018Hologic BuyNeedham & Company, LLC
DatumRatingAnalyst
09.10.2018Hologic NeutralUBS AG
03.05.2018Hologic HoldCanaccord Adams
03.08.2017Hologic Sector PerformRBC Capital Markets
28.04.2016Hologic HoldNeedham & Company, LLC
07.01.2016Hologic Equal WeightBarclays Capital
DatumRatingAnalyst
30.07.2015Hologic UnderweightBarclays Capital
07.01.2015Hologic UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Hologic IncShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"